Invitae Corporation

Q3 revenue was $121.2 million, down 9% reported due to exits of RUO kit, IVF, and some international businesses, but up approximately 4% year over year on a pro forma basis and roughly flat sequentially. Non-GAAP gross margin was 52.4%, compared with 45.9% in Q3 2022 and 49.8% in Q2 2023. Non-GAAP operating expenses were $122 million, or 101% of revenue, versus $150 million a year ago and $158 million in Q2. Cash, cash equivalents, restricted cash, and marketable securities totaled $265 million at quarter end. Ongoing cash burn was approximately $64 million, improving 41% year over year, and revenue per patient was $474 versus $459 in the prior period. Full-year 2023 guidance was reaffirmed for revenue of $480 million to $500 million, non-GAAP gross margin of 48% to 50%, and ongoing cash burn of $220 million to $245 million. Management said reported cash burn will exceed ongoing cash burn in 2023 because of the voluntary repayment of the term loan and related prepayment penalty.

Ken Knight framed the quarter as evidence that Invitae’s shift toward higher-quality revenue and lower unit costs is working. He highlighted nine straight quarters of non-GAAP gross margin expansion, progress in collections, and two regulatory wins: FDA authorization for the hereditary cancer panel and approval for the enhanced PCM assay. His tone was confident but cautious, repeatedly stressing that the company still has work to do on liquidity, capital structure, and rebuilding parts of the oncology pipeline.

Ana Schrank focused on the financial cleanup and improving operating metrics. She said revenue was $121 million, non-GAAP gross margin was 52.4%, non-GAAP operating expenses fell to $122 million, and ongoing cash burn was about $64 million, with sequential burn affected by a $5 million semiannual interest payment, roughly $4 million from a contract renegotiation, and another $4 million of acquisition-related payments. She also noted $265 million in cash and equivalents at quarter end and reaffirmed the 2023 guide for $480 million to $500 million of revenue, 48% to 50% gross margin, and $220 million to $245 million of ongoing cash burn.

Analysts pressed on whether the enhanced PCM assay addresses Natera-related litigation risk, and Ken Knight said the company believes the new chemistry and process changes appropriately address the disputed items, though he would not get into detailed specifics. Questions also centered on whether commercial payer reimbursement headwinds in oncology would resolve by year-end; management said the benefit is already improving but expects the full-year impact to show up in 2024. Other questions focused on the capital-structure review, gross margin durability, and the PCM reimbursement pipeline, with management saying early 2024 should bring more clarity on reimbursement submissions and that the special committee is working with urgency but without a set timeline.